Medarex, Inc.

Medarex, Inc.

Medarex is building the ultimate monoclonal antibody. Its UltiMAb technology utilizes transgenic mice whose antibody gene expression is suppressed to create fully human monoclonal antibodies (single-source proteins). Medarex has more than 40 antibodies for cancer, rheumatoid arthritis, and other autoimmune, inflammatory, and infectious diseases in clinical trials or pre-trial stages. The company has partnerships with numerous pharma and biotech firms including Genmab, which has licensed antibody therapies for leukemia, arthritis, and other conditions. Other development partners include Pfizer, Amgen, Eli Lilly, and Kirin. Another major collaborator, Bristol-Myers Squibb, acquired Medarex for $2.4 billion in 2009.

Contact Details

Office Address

Medarex, Inc.
707 State Road
Princeton, NJ, USA 08540-1437
Phone: (609) 430-2880
Fax: (609) 430-2850


Chairman Emeritus

Irwin Lerner

Chairman, President, and CEO

Howard H. Pien

Business Reviews for Medarex, Inc.

Related Companies